We recently published 10 Stocks Everyone’s Discussing Amid Latest Earnings Season. AbbVie Inc. is one of the stocks everyone’s discussing.
Jason Snipe, the Founder and Chief Investment Officer of Odyssey Capital Advisors, recommended investors to “stay long” AbbVie Inc during a recent program on CNBC. ABBV shares are up 21% so far this year.
Carillon Eagle Growth & Income Fund stated the following regarding AbbVie Inc. in its second quarter 2025 investor letter:
“AbbVie Inc.’s (NYSE:ABBV) shares were a detractor for the portfolio in the second quarter. We attribute the weakness primarily to the underperformance of the broader biopharmaceutical industry, which is under pressure as it navigates policy threats from the Trump administration surrounding both tariffs on the pharmaceutical sector and a proposal to explore most-favored nation prescription drug pricing.”
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
